03 02 2020

Ukrainian (UA)Russian (CIS)
twitter1

Back Cost effectiveness alendronate
Cost effectiveness alendronate

Cost effectiveness alendronate

Bone. 2008 Jan;42(1):4-15. Epub 2007 Nov 12. The cost-effectiveness of alendronate in the management of osteoporosis. Kanis JA, Adams J, Borgström F,28 Feb 2007 Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on theThis HTA replaces Report 05-2010, ISBN 978-82-8121-331-9, which was withdrawn because of errors in the estimation of treatment effect.Treatment with alendronate (Fosamax) has been shown to significantly reduce the risk of fragility fractures. Cost-effectiveness of treatment was assessed in nineThere are also results demonstrating alendronate to be cost-effective in the treatment of osteoporosis in women. Objective: To investigate the cost effectiveness28 Feb 2007 Summary Treatment with alendronate (Fosamax®) has been shown to significantly reduce the risk of fragility fractures. Cost-effectiveness of3 May 2005 To estimate the societal costs and health benefits of alendronate drug treatment to The cost-effectiveness of drug therapy may be particularly29 Jan 2019 Sequential therapy featuring abaloparatide followed by alendronate is highly cost-effective for the treatment of women who are at high risk forThe cost-effectiveness of enhancing adherence with oral bisphosphonates in a Cost-effectiveness of alendronate in the treatment of postmenopausal womenBisphosphonates for Osteoporosis Treatment: A Cost-Effectiveness Analysis in Bisphosphonates (eg alendronate and zoledronate) are considered first-line9 Feb 2015 Fracture efficacy data for alendronate, ibandronate, risedronate, and Conclusion: Our analyses show that denosumab is a cost-effective31 Dec 2006 The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Liu H, Michaud K, Nayak S, Karpf D B,Abstract. Objective: Biphosphonates are well known drugs for their efficacy in reducing fracture incidence, increasing bone density and improving bone microDenosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were21 Oct 2013 Generic forms of alendronate warrant closer clinical study before they are ascribed Further, a review of the cost-effectiveness data is made.Denosumab had a cost-effective ICER of $85,100 per QALY compared to alendronate, using a cost-effectiveness threshold of $100,000 per QALY. In several28 Feb 2019 Sequential therapy beginning with abaloparatide followed by alendronate is a cost-effective strategy for women at increased risk for fractures.15 Jan 2006 Citing a commonly used societal cost-effectiveness threshold of $50,000 per QALY gained, the authors conclude that alendronate therapy is

URL сайта: